{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:02:23Z","timestamp":1788292943778,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10072-023-07194-w","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:01:46Z","timestamp":1700240506000},"page":"2461-2469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy of anti-amyloid-\u00df monoclonal antibody therapy in early Alzheimer\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-0932","authenticated-orcid":false,"given":"Julyana M.","family":"Dantas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mutarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denilsa D. P.","family":"Navalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Dagostin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro H. C. L.","family":"Romeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alleh","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1vio","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Caramelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"7194_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q (2022) Alzheimer\u2019s disease: epidemiology and clinical progression. Neurol Ther 11:553\u2013569. https:\/\/doi.org\/10.1007\/s40120-022-00338-8","journal-title":"Neurol Ther"},{"key":"7194_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14:32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5","journal-title":"Mol Neurodegener"},{"key":"7194_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9758\/cpn.2017.15.1.1","volume":"15","author":"S Kocahan","year":"2017","unstructured":"Kocahan S, Do\u011fan Z (2017) Mechanisms of Alzheimer\u2019s disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, Tau Protein and Other Risk Factors. Clin Psychopharmacol Neurosci 15:1\u20138. https:\/\/doi.org\/10.9758\/cpn.2017.15.1.1","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"7194_CR4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, Khoury JE et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14:388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"key":"7194_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","volume":"119","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ, Shiri-Feshki M (2009) Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119:252\u2013265. https:\/\/doi.org\/10.1111\/j.1600-0447.2008.01326.x","journal-title":"Acta Psychiatr Scand"},{"key":"7194_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1017\/S1041610205002450","volume":"18","author":"L Frank","year":"2006","unstructured":"Frank L, Lloyd A, Flynn JA et al (2006) Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants. Int Psychogeriatr 18:151\u2013162. https:\/\/doi.org\/10.1017\/S1041610205002450","journal-title":"Int Psychogeriatr"},{"key":"7194_CR7","first-page":"809","volume":"7","author":"DP Rice","year":"2001","unstructured":"Rice DP, Fillit HM, Max W et al (2001) Prevalence, costs, and treatment of Alzheimer\u2019s disease and related dementia: a managed care perspective. Am J Manag Care 7:809\u2013818","journal-title":"Am J Manag Care"},{"key":"7194_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2012.05.2117","volume":"9","author":"P Lin","year":"2013","unstructured":"Lin P, Neumann PJ (2013) The economics of mild cognitive impairment. Alzheimers Dement 9:58\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2012.05.2117","journal-title":"Alzheimers Dement"},{"key":"7194_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Logroscino G, Imbimbo BP (2019) A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat Rev Neurol 15:73\u201388. https:\/\/doi.org\/10.1038\/s41582-018-0116-6","journal-title":"Nat Rev Neurol"},{"key":"7194_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E et al (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther 9:95. https:\/\/doi.org\/10.1186\/s13195-017-0318-y","journal-title":"Alzheimers Res Ther"},{"key":"7194_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M et al (2016) Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther 8:18. https:\/\/doi.org\/10.1186\/s13195-016-0189-7","journal-title":"Alzheimers Res Ther"},{"key":"7194_CR12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S, Bittner T, Sink KM et al (2022) Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol 79:1113. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2909","journal-title":"JAMA Neurol"},{"key":"7194_CR13","doi-asserted-by":"publisher","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. https:\/\/doi.org\/10.14283\/jpad.2022.30","DOI":"10.14283\/jpad.2022.30"},{"key":"7194_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/jgs.17692","volume":"70","author":"MJ DiStefano","year":"2022","unstructured":"DiStefano MJ, Alexander GC, Polsky D, Anderson GF (2022) Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: a nationally representative survey. J Am Geriatr Soc 70:1685\u20131694. https:\/\/doi.org\/10.1111\/jgs.17692","journal-title":"J Am Geriatr Soc"},{"key":"7194_CR15","doi-asserted-by":"publisher","unstructured":"Aisen PS, Cummings J, Doody R et al (2020) The future of anti-amyloid trials. J Prev Alzheimers Dis:1\u20136. https:\/\/doi.org\/10.14283\/jpad.2020.24","DOI":"10.14283\/jpad.2020.24"},{"key":"7194_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.neurol.2022.06.012","volume":"178","author":"N Villain","year":"2022","unstructured":"Villain N, Planche V, Levy R (2022) High-clearance anti-amyloid immunotherapies in Alzheimer\u2019s disease. Part 1: meta-analysis and review of efficacy and safety data, and medico-economical aspects. Rev Neurol (Paris) 178:1011\u20131030. https:\/\/doi.org\/10.1016\/j.neurol.2022.06.012","journal-title":"Rev Neurol (Paris)"},{"key":"7194_CR17","doi-asserted-by":"publisher","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2023.13239","DOI":"10.1001\/jama.2023.13239"},{"key":"7194_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"7194_CR19","first-page":"4285","volume-title":"GRADUATE I AND II: findings of two phase iii randomized placebo-controlled studies assessing the efficacy and safety of subcutaneous gantenerumab in early Alzheimer\u2019s disease (AD) (S26.010). In: Tuesday, April 25","author":"J Smith","year":"2023","unstructured":"Smith J, Donohue MC, Gruendl E et al (2023) GRADUATE I AND II: findings of two phase iii randomized placebo-controlled studies assessing the efficacy and safety of subcutaneous gantenerumab in early Alzheimer\u2019s disease (AD) (S26.010). In: Tuesday, April 25. Lippincott Williams & Wilkins, p 4285"},{"key":"7194_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"key":"7194_CR21","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"7194_CR22","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions, 2nd ed. John Wiley & Sons, Chichester (UK)","DOI":"10.1002\/9781119536604"},{"key":"7194_CR23","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"7194_CR24","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","volume":"90","author":"JL Cummings","year":"2018","unstructured":"Cummings JL, Cohen S, Van Dyck CH et al (2018) ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology 90:e1889\u2013e1897. https:\/\/doi.org\/10.1212\/WNL.0000000000005550","journal-title":"Neurology"},{"key":"7194_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","volume":"10","author":"S Salloway","year":"2018","unstructured":"Salloway S, Honigberg LA, Cho W et al (2018) Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE). Alzheimers Res Ther 10:96. https:\/\/doi.org\/10.1186\/s13195-018-0424-5","journal-title":"Alzheimers Res Ther"},{"key":"7194_CR26","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C et al (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med 384:1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"key":"7194_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370:311\u2013321. https:\/\/doi.org\/10.1056\/NEJMoa1312889","journal-title":"N Engl J Med"},{"key":"7194_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M et al (2018) Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med 378:321\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1705971","journal-title":"N Engl J Med"},{"key":"7194_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370:322\u2013333. https:\/\/doi.org\/10.1056\/NEJMoa1304839","journal-title":"N Engl J Med"},{"key":"7194_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S et al (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther 13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8","journal-title":"Alzheimers Res Ther"},{"key":"7194_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"7194_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","volume":"5","author":"JS Andrews","year":"2019","unstructured":"Andrews JS, Desai U, Kirson NY et al (2019) Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials. Alzheimers Dement Transl Res Clin Interv 5:354\u2013363. https:\/\/doi.org\/10.1016\/j.trci.2019.06.005","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"7194_CR33","doi-asserted-by":"publisher","unstructured":"Lansdall CJ, McDougall F, Butler LM et al (2022) Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer\u2019s disease. J Prev Alzheimers Dis. https:\/\/doi.org\/10.14283\/jpad.2022.102","DOI":"10.14283\/jpad.2022.102"},{"key":"7194_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","volume":"83","author":"A Schrag","year":"2012","unstructured":"Schrag A, Schott JM, Alzheimer\u2019s Disease Neuroimaging Initiative (2012) What is the clinically relevant change on the ADAS-Cog? J Neurol Neurosurg Psychiatry 83:171\u2013173. https:\/\/doi.org\/10.1136\/jnnp-2011-300881","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7194_CR35","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1212\/WNL.59.7.1034","volume":"59","author":"M Storandt","year":"2002","unstructured":"Storandt M, Grant EA, Miller JP, Morris JC (2002) Rates of progression in mild cognitive impairment and early Alzheimer\u2019s disease. Neurology 59:1034\u20131041. https:\/\/doi.org\/10.1212\/WNL.59.7.1034","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07194-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07194-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07194-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:40:38Z","timestamp":1715312438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07194-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["7194"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07194-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review and meta-analysis. No ethical approval was required as no new patient data was collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Dr. Caramelli declares participation in an advisory board for Roche, the sponsor for CREAD, CREAD2, and SCarlet RoAD. Dr. Caramelli has also developed material for continuous medical education and participation as a speaker in symposia sponsored by Ach\u00e9, Knight Therapeutics, Roche, and Torrent laboratories. The remainder of the authors have no competing interests to declare. The authors did not receive support from any organization for the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}